Gedeon Richter Plc - Company Profile
Powered by 
All the sales intelligence you need on Gedeon Richter Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Gedeon Richter Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Gedeon Richter Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Richter Gedeon Plc (Richter) researches, manufactures and commercializes pharmaceutical products. Its product line includes original, generic and licensed products. The company offers a biotechnology platform, medicines for central nervous system disorders, over-the-counter (OTC) medicines, antibiotics, and medicines for the treatment of motor organs. The company has an operational presence in 50 countries globally. The company operates through two reportable business segments: Pharmaceuticals and Other. In FY2025, the company’s capital expenditure stood at HUF66,404 million.
R&D Overview
Richter has a strong focus on R&D activities and has a dedicated team involved in the development of new products and the enhancement of existing products. The company is developing drugs for treating women’s diseases and CNS disorders. Its research activities focus on the development of original small molecules, recombinant biotechnology, and generic product development. The company has made significant advancements in the CNS field with cariprazine. The company has established successful partnerships, such as with AbbVie, to co-develop and commercialize novel treatments for neuropsychiatric diseases. As of December 31, 2025, Richter had 11 CNS original R&D projects, with eight in the preclinical phase and three in the clinical phase. The company is also expanding its Women's Healthcare product portfolio and has acquired assets from Mithra and BCI to enhance its R&D capabilities in this area. It aims to maintain cost efficiency in R&D and seeks early-stage partnerships for promising projects. Richter's process development activities and bioequivalence studies on various active pharmaceutical ingredients and finished products have significantly enhanced the female healthcare product portfolio. In FY2025, the company spent HUF91,185 million on its R&D activities, which, as a percentage of revenue, stood at 9.8%
Business Segments
Overview
Includes the company's members who offer auxiliary services to pharmaceuticals, wholesale and retail segments.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Researches and develops new chemical entities (NCEs), conducts recombinant biotechnological activities and the development of generic products with a focus in the areas of biotechnology (BIO), gynecology, female healthcare and diseases related to the central nervous system (CNS). -Offers female healthcare drugs such as female contraceptive products, products for menopause, hormone replacement therapy products, osteoporosis medications, and treatments for gynecological infections. -The CNS products include treatments for psychiatric, neurological and behavioral disorders. -It also offers a wide range of general medicines for several health problems. Views development of Women’s Healthcare product portfolio, research of new chemical entities research of new chemical entities.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer